penfluridol has been researched along with Carcinoma, Pancreatic Ductal in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ali Sayed, AA; Anant, S; Banerjee, T; Baranda, J; Butler, M; Choudhury, S; Coppola, D; Dandawate, P; Dhar, A; Ghosh, C; Jensen, RA; Kasi, A; Kaushik, G; Malafa, M; Manzardo, A; Padhye, SB; Ramamoorthy, P; Saha, S; Santra, S; Soares, MJ; Standing, D; Subramaniam, D; Sun, W; Tawfik, O; Thomas, SM; Umar, S; Weir, SJ | 1 |
1 other study(ies) available for penfluridol and Carcinoma, Pancreatic Ductal
| Article | Year |
|---|---|
Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice.
Topics: Animals; Antipsychotic Agents; Autophagy; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Drug Discovery; Gene Knockdown Techniques; Humans; Injections, Intraperitoneal; Janus Kinase 2; Male; Mice; Pancreas; Pancreatic Neoplasms; Penfluridol; Prolactin; Receptors, Prolactin; Signal Transduction; Spheroids, Cellular; STAT3 Transcription Factor; Tissue Array Analysis; Xenograft Model Antitumor Assays | 2020 |